Interviews

Steven Lucio of Novation discusses why now is the time for pharmacists to educate themselves about biosimilars and the complexities surrounding biologic manufacturing.

Mitchell Katz, PhD, executive director, medical research operations at Purdue Pharma L.P., explains the function of a Contract Research Organization (CRO) and its role in drug development.

Jonathan G. Marquess, PharmD, CDE, explains why he decided to focus on caring for diabetes patients at his pharmacy.

Robert Granko, PharmD, MBA, discusses how his hospital system developed a model that used data to determine how pharmacists should be positioned.

Leigh Ann Bruhn, director of Avalere Health, notes that limited distribution for specialty pharmaceuticals can improve a manufacturer's data capture capabilities.

Joe Moose, PharmD, discusses what it means to shift from a volume-driven business to a value-driven business.

Edmund Pezalla, MD, MPH, national medical director, pharmacy policy and strategy at Aetna, explains how drugs that have been deemed "failures" can sometimes become effective treatments for other conditions.

Pharmacy Times Health-System Edition Editor Stephen F. Eckel, PharmD, MHA, describes his most rewarding experiences working with pharmacy students.

In this video, Todd Speranzo of Avella talks about how to create video content that is compelling to patients.

Stephan Foster, PharmD, FAPha, discusses the history of preventive medicine in the the pharmacy.

Robert Granko, PharmD, MBA, discusses the move to use business intelligence and data analytics in health systems to better understand what is driving cost increases.

In this video from the 2013 Armada Specialty Pharmacy Summit, Mark Zitter of Zitter Health Insights discusses stakeholder views on copay cards.

Pharmacy Times Health-System Edition Editor Stephen F. Eckel offers advice to pharmacy students who are considering a career in health-system pharmacy.

David G. Miller, RPh, discusses the roles of the FDA and state boards of pharmacy in regulating compounding pharmacies.

A patient who thought chronic pain meant she would never work again or have a normal family life found relief at the Nebraska Medical Center.

David G. Miller, RPh, discusses whether and how regulation of compounding pharmacies needs to change.

Specialty Pharmacy Times contributor Quintin Jessee discusses why he chose a career in specialty pharmacy and the new opportunities that are emerging in this industry.

A patient with unyielding pain for a decade learns how to manage her pain at the Mayo Clinic's Pain Rehabilitation Center.

Sherilyn Driscoll, MD, a pediatrics physiatrist at the Mayo Clinic, discusses how treatment of chronic pain in children has changed.

Mark Zitter, CEO at Zitter Health Insights, explains how the growth of Accountable Care Organizations may impact specialty drug management in the near future.

Bill Sullivan of the Specialty Pharmacy Association of America describes the growth of the specialty pharmacy industry and the factors that prompted the formation of SPAARx.

Michael Einodshofer of Walgreens identifies the various charges that can be included in the total cost of an infusion in a hospital setting.

This video discusses the effect of thiazide diuretics on serum sodium concentration.

This animation illustrates the effect of severe over-hydration on the central nervous system.

Clinical and exam preparation instructor Roger Seheult, MD, provides the first part of a 4-part course explaining hyponatremia.

Carrie Hurwitz, MBA, director, corporate strategy and business development at McKesson, explains why pharmacists may be the health care providers best positioned to recruit patients into clinical trials.

Einodshofer of Walgreens explains that it can be difficult to convince oncologists with hospital-owned oncology practices to send patients to alternative treatment sites.

Some pharmaceutical manufacturers choose a limited distribution model for their specialty product so that they can ensure all standards of care and reporting associated with that therapy are upheld, noted Duane Barnes, senior vice president, consumer delivery, Prime Therapeutics, at the 2013 Armada Specialty Pharmacy Summit.

Prime Therapeutics projects that by 2017, the cost of specialty pharmaceuticals will be half the cost of all pharmacy claims. Therefore, noted Duane Barnes, senior vice president, consumer delivery at Prime Therapeutics, it is important for a PBM to align its medical and pharmacy policies.

Debbie Stern of Rxperts highlights the various "unknowns" surrounding the potential cost savings of biosimilar products, such as interchangeability and the possible need for additional clinical trials.